The risk of recurrence in stage II colon cancer patients is not easily predicted with traditional clinical and pathologic factors. We explore the success of the Oncotype DX® Colon Cancer Assay in improving the ability to quantify recurrence risk fo...
Key announcements from Threshold and Sunesis, pivotal data from large caps players like BMS and Roche, and a flurry of FDA approval decisions on cancer drugs are due from now until early-mid 2015. OBR reports on some upcoming clinical catalysts. ...
Anti-angiogenesis inhibitors like Avastin have changed the cancer treatment landscape for the better but they also present a number of challenges to clinicians. Not the least of these is finding reliable biomarkers to improve their clinical efficacy ...
The treatment paradigm for metastatic castrate-resistant prostate cancer (mCRPC) is rapidly changing as newer, less toxic agents are introduced for use in both chemo-naïve patients and in later settings. We dissect the shifting trends and look at al...